

RESEARCH ARTICLE


Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model

Yen-Bo Su^{1,2}, Tzu-Hao Li^{2,3,4,5}, Chia-Chang Huang^{1,2,4}, Hung-Cheng Tsai^{1,2}, Shiang-Fen Huang^{2,6}, Yun-Cheng Hsieh^{2,7}, Ying-Ying Yang^{1,2,4,7,8}*, Yi-Hsiang Huang^{2,7}, Ming-Chih Hou^{2,7}, Han-Chieh Lin^{2,7}*

1 Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, **2** Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, **3** Division of Allergy and Immunology, Taipei Veterans General Hospital, Taipei, Taiwan, **4** Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, **5** Chia-Yi Branch of Taichung Veterans General Hospital, Chiayi, Taiwan, **6** Division of Infection, Taipei Veterans General Hospital, Taipei, Taiwan, **7** Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan, **8** Division of General Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

* These authors contributed equally to this work.

* yanggy@vghtpe.gov.tw (YYY); hclin@vghtpe.gov.tw (HCL)



OPEN ACCESS

Citation: Su Y-B, Li T-H, Huang C-C, Tsai H-C, Huang S-F, Hsieh Y-C, et al. (2018) Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model. PLoS ONE 13(4): e0194867. <https://doi.org/10.1371/journal.pone.0194867>

Editor: Jordi Gracia-Sancho, IDIBAPS Biomedical Research Institute, SPAIN

Received: October 28, 2017

Accepted: March 12, 2018

Published: April 23, 2018

Copyright: © 2018 Su et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files ([S3 File](#)).

Funding: We especially thank Yun-Ru Wang, Fan-Yi Jhan, Che-Jui Chang and Yen-Ling Lin for their excellent technical supports. This work was entirely supported by research grants NSC-102-2314-B-010-036-MY3 and from the National Science

Abstract

Vitamin D deficiency and up-regulated TNF α -related signals are reported to be involved in abnormalities including intestinal hyper-permeability, bacterial translocation, systemic/portal endotoxemia, intestinal/adipose tissue/hepatic inflammation, and hepatic steatosis in non-alcoholic steatohepatitis (NASH). This study aims to explore the molecular mechanisms and effects of chronic calcitriol [1,25-(OH)₂D₃, hormonal form of vitamin D] on gut-adipose tissue-liver axis abnormalities using a high-fat diet (HFD)-fed rat model of NASH. In HFD-fed obese rats on a 10-week calcitriol (0.3 μ g/kg/TIW) or vehicle treatment (NASH-vit. D and NASH-V rats) regime, various *in vivo* and *in vitro* experiments were undertaken. Through anti-TNF α -TNFR1-NF κ B signaling effects, chronic calcitriol treatment significantly restored plasma calcitriol levels and significantly improved vitamin D receptor (VDR) expression in monocytes and the small intestine of NASH-vit. D rats. Significantly, plasma and portal endotoxin/TNF α levels, bacterial translocation to mesenteric lymph nodes, plasma DX-4000-FITC, fecal albumin-assessed intestinal hyper-permeability, over-expression of TNF α -related immune profiles in monocytes, inflammation of intestinal/mesenteric adipose tissue (MAT)/liver and hepatic steatosis were improved by chronic calcitriol treatment of NASH rats. Additionally, *in vitro* experiments with acute calcitriol co-incubation reversed NASH-V rat monocyte supernatant/TNF α -induced monolayer barrier dysfunction in caco-2 cells, cytokine release from MAT-derived adipocytes, and triglyceride synthesis by lean-V rat hepatocytes. Using *in vivo* and *in vitro* experiments, our study reported calcitriol signaling in the gut as well as in adipose tissue. Meanwhile, our study suggests that restoration of

Council, and V106EA-007, VGHUST105-GI-2-2 and by the Taipei Veterans General Hospital.

Competing interests: The authors have declared that no competing interests exist.

systemic and intestinal vitamin D deficiency using by chronic vitamin D treatment effectively reduces TNF α -mediated immunological abnormalities associated with the gut-adipose tissue-liver axis and hepatic steatosis in NASH rats.

Introduction

Higher levels of plasma and intestinal lipopolysaccharide (LPS, also called endotoxin) are noted in nonalcoholic steatohepatitis (NASH) patients than in healthy subjects [1,2]. LPS is the main stimulator to induce tumor necrosis factor- α (TNF α) release from immune cells [1]. Compared to healthy controls, significantly high LPS-stimulated TNF α production is observed in cultured whole blood cells from NASH patients [2]. In NASH, increased TNF α can exacerbate intestinal inflammation and mucosal barrier disruption [3–5]. In the inflamed intestinal epithelium, TNF α produced from infiltrated immune cells further results in systemic/portal inflammation and endotoxemia [3–6]. So, NASH is characterized by remarkable intestinal hyper-permeability, epithelial tight junctions disruption and endotoxemia [5,7].

In obese animals, intestinal dysbiosis is associated with increased macrophage infiltration and high cytokine release by mesenteric adipose tissue (MAT), which is positioned near the intestine and is drained by the portal vein [8]. Additionally, intestinal hyper-permeability and MAT inflammation are involved in the pathogenesis of portal endotoxemia and hepatic steatosis [9,10]. Chronic intestinal/MAT inflammation and a disrupted intestinal barrier result in bacterial translocation and the progression of NAFLD to NASH [9,11,12]. Notably, in NASH, intestinal hyper-permeability, systemic/portal endotoxemia, and systemic/intestinal/MAT inflammation are initiated by TNF α -released from activated immune cells [2,4,5, 7,9,10]. So, anti-TNF α agents have the potential to simultaneously ameliorate the aforementioned abnormalities in NASH [9,10, 13,14].

In cultured human peripheral blood monocytes, 1,25-(OH) $_2$ D $_3$, the hormonal form of vitamin D, is able to dose-dependently inhibit LPS-stimulated TNF α production [15]. Serum TNF α levels are negatively correlated with serum vitamin D concentrations in healthy women [16]. Among NASH patients, low serum vitamin D concentrations are closely associated with severe hepatic steatosis and inflammation [17]. Vitamin D receptor (VDR) is a nuclear receptor that mediates most of the known functions of vitamin D, including its anti-TNF α effects. Chronic mucosal inflammation and TNF α -induced down-regulation of gut epithelial VDR can be observed in cases of inflammatory bowel disease [18]. Through direct epithelial VDR up-regulation and indirect TNF α inhibition, vitamin D analog displays mucosal protection and anti-inflammatory effects [19].

Through histological evaluation in rat livers, vitamin D treatment from 6- weeks (time point for diet-induced NASH) to 12- weeks (time point for diet-induced fibrosis) after diet feeding has been found to prevent the progression of NASH to hepatic fibrosis [20]. With histological and gene expression measurements, depletion of vitamin D in a westernized diet exacerbates NAFLD through the activation of toll-like receptor (TLR) in NASH rat livers [21]. In addition to prevent the progression of NASH, vitamin D treatment reduced the serum free fatty acid/triglyceride levels, hepatic thiobarbituric acid-reactive substances (TBARS) levels, and hepatocyte apoptosis in rats [22]. Besides reducing hepatic steatosis, supplementation of vitamin D in the diet alleviates high-fat diet (HFD)-induced overweight and hyperinsulinemia by up-regulating hepatic lipolytic genes and adipose-tissue energy expenditure genes

expressions in mice [23]. Especially in adipose tissue of obese rats, depletion of vitamin D in diet exacerbated HFD-increased adipose size by up-regulation of lipogenic/inflammatory genes and macrophage infiltration [24]. Further study reported that vitamin D treatment reduces hepatic triglyceride levels, hepatic nonalcoholic fatty liver disease activity score, and hepatic CD68/TGF β 1/ α SMA expression, as well as decreases the levels of serum aspartate aminotransferase and alanine aminotransferase in NASH rats [25]. Significantly, vitamin D treatment up-regulates nutrition sensing genes expression in adipose tissue of HFD-fed diabetic mice [26]. Chronic administration of vitamin D-enriched mushroom extracts reduces HFD-induced body fat accumulation, hepatic inflammation/steatosis (by histology and EchoMRI) and serum triglyceride/cytokine levels in mice [27].

To summarize the abovementioned studies [20–27], the therapeutic potential-associated with the anti-hepatic steatosis effects of vitamin D in the parallel abnormalities in circulation and the intestinal and adipose tissue of NASH animals have not been fully explored.

Accordingly, the present study aimed to evaluate the molecular mechanisms and effects of chronic vitamin D treatment on the aforementioned gut-adipose tissue-liver axis abnormalities using a rat model of diet-induced NASH.

Materials and methods

Animals

Male Sprague-Dawley (SD) rats (4-week old) were purchased from Charles River Japan, Inc. (Yokohama, Japan) and caged at 22°C on a 12-hour light-dark cycle with free access to water. Normal-chow-diet (NCD, Laboratory Autoclavable Rodent Diet 5010) or high-fat-diet (HFD, D12492) were given for 14 weeks to form the lean or NASH groups. From 4 to 14 weeks after NCD/HFD feeding, lean rats (Lean-V/lean-vit.D, $n = 6$ in each group) and NASH rats (NASH-V/NASH-vit.D, $n = 9$ in each group) received 10-weeks of either vehicle or 0.3 $\mu\text{g}/\text{kg}/\text{TIW}$ of 1,25(OH) $_2$ D $_3$ by gastric gavage.

This study was approved by the Animal Experiments Committee of Yang-Ming University and was performed according to the “Guide for the care and use of laboratory animals” prepared by the National Academy of Science, USA and the ARRIVE guidelines [28]. All efforts were made to minimize animal numbers necessary to produce reliable results and suffering was reduced by administering anesthetics (zoletil and xylocaine). At the end of the experiments, the rats were euthanized with 2–3 times the anesthetic dose of zoletil.

Experimental design

Three days before the following experiments, *in vivo* intestinal permeability was measured in all rats. Subsequently, heparinized portal vein and whole-body blood was collected to separate peripheral blood mononuclear cells (PBMCs). Meanwhile, the liver, the intestine [duodenum, ileum, cecum and colon], mesenteric fats [the fat surrounding the gastrointestinal tract from the gastroesophageal sphincter to the end of the rectum], and the mesenteric lymph nodes [MLN, drained LNs from the terminal ileum, cecum and ascending colon] were collected by aseptic dissection. The macrophage numbers in the intestine and MAT were measured by flow cytometry. Primary monocytes (CD14 $^+$ cells) were isolated from PBMCs and adipocytes were isolated from MAT.

In order to assess the *in vitro* effects of 1,25(OH) $_2$ D $_3$ on TNF α and NASH-CM-induced cascades, the intestinal epithelial caco-2 cells and lean-V rat hepatocytes were cultured with/without different concentrations of 1,25(OH) $_2$ D $_3$ [10^{-11} , 10^{-9} , 10^{-7} M].

Intestinal permeability

This measurement was based on the intestinal permeability to 4,000-Da fluorescent-dextran [DX-4000-fluorescein isothiocyanate (FITC), FD4000; Sigma-Aldrich, St. Louis, MO] by the analysis of time-dependent serum DX-4000-FITC concentration curves and area under curves (AUCs) [4,6,8]. For validation, the intestinal permeability was re-assessed by measurement of albumin content in the rat feces using ELISA kits (MyBioSource, Inc, San Diego, California, USA).

Measurements of cytokines/cytokines receptors in PBMC-derived monocytes

After intestinal permeability measurement, heparinized-blood was collected from all rats for PBMCs ($25\text{--}30 \times 10^6$) isolation. PBMCs suspensions were depleted of neutrophils, NK cells, T-cells, and B-cells using immuno-magnetic sorting beads for magnetic cell sorting (MACS) by negative selection with Ly6G-biotin, CD56-biotin, CD3-biotin, and CD19-biotin antibodies. Further, primary rat monocytes (CD14⁺ cells) were isolated from above mentioned cell suspension as the CD14-biotin-positive, Ly6G/CD56/CD3/CD19-negative fraction separated by anti-CD14 mAb-coupled magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany) through an MACS positive selection column. For flow cytometry analysis, monocytes (1×10^6 /ml/well) were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. Dead cells were then stained with propidium iodide (BD Biosciences) whereas live cells (monocyte) were stained, gated, and quantified for CD14/VDR, CD14/TNF α , CD14/NF κ B, CD14/TNFR1 and CD14/TNFR2 double positive cells.

Monocytes were incubated for 20 h and cell free supernatants were harvested to measure TNF α , IL-6 and MCP-1 levels using ELISA kits (R&D, Minneapolis, MN). The supernatants of 48-hour-cultured NASH-V rat monocytes were used as conditioned medium (NASH-V-CM) to evaluate its effect on caco-2 cell monolayer integrity, lean-V rat adipocyte cytokine release and lean-V rat hepatocytes steatosis.

Plasma cytokines/chemokines level

Plasma glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and triglyceride levels were measured using a standard auto SMAC analyzer (Roche Diagnostics GmbH, ANNHEIM, Germany). Using pyrogen-free water (Lonza, Basel, Switzerland) and a pyrogen-free container, portal vein/plasma endotoxin, TNF α and LPS-binding protein (LBP), plasma/intestine calcitriol [1,25(OH)₂D₃] were measured using ToxinSensor Chromogenic LAL Endotoxin Assay Kit (GenScript USA Inc.) and cytokines/calcitriol ELISA Kits (R&D Systems INC., Minneapolis, MN). TG content in liver homogenate was measured by a TG Colorimetric Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA).

Various intestinal and mesenteric adipose tissues (MAT) markers

Intestinal caspase-3 activity was determined. The protein and mRNA levels in the rat intestine, rat MAT-derived adipocytes, caco-2 cells, and rat hepatocytes were measured using appropriate antibodies and primers (S1 Table). For flow cytometry analysis, red blood cells (RBCs) present in 1 gram of intestinal and MAT homogenate were lysed using Pharm Lyse (BD Biosciences); the remaining cells (3×10^6 cells/gram tissue) were suspended in PBS containing 2mM EDTA and exposed to FcBLOCK (BD Biosciences) for 20 minutes. To identify macrophage infiltration ($\times 10^3$ /gram tissue) in tissues, the cells (3×10^5 cells) were then labeled with FITC-conjugated F4/80 and PE-conjugated CD11b antibodies for quantification of CD11b(+)F4/80(+) cells

by flow cytometry using a FACSalibur analyzer (BD Biosciences), whereas dead cells were identified using propidium iodide (BD Biosciences).

Histological examination

NAFLD activity scores (NASs) were evaluated for rat liver samples. Duodenal tissue samples were used for immunohistochemical (IHC) studies of TNF α , TNFRI, and active caspase-7 expression.

Bacterial translocation (BT) and fecal analysis

BT was defined as positivity of a bacterial culture in sterilized liquefied LMN. Three stool pellets (one per day) from each rat were pooled, dried and stored at 80°C to allow DNA extraction for quantification of the total number of bacterial cells, including intestinal *Lactobacillus* spp., *Bifidobacterium* spp. and *Bacteroides-Prevotella* spp.

NASH-V-CM/TNF α -stimulated cytokines release from rat MAT-derived adipocytes

Lean-V and NASH-V adipocytes were isolated from rat MATs to measure time-dependent cytokine release [29]. Next, cytokines/cytokine receptor levels in the supernatant and *mRNAs* levels in the cell lysates of lean-V rat adipocytes treated with incremental concentration of 1,25(OH)₂D₃-treated were measured after stimulation with either TNF α or NASH-V-CM.

In vitro effects of calcitriol on NASH-V-CM/TNF α -induced caco-2 cell monolayer barrier dysfunction

Differentiated caco-2 monolayer cells (5×10^5) were treated with buffer, TNF α , or NASH-V-CM. Subsequently, 1,25(OH)₂D₃ was applied or was not to the apical and basolateral compartments for 48 hours. Next, barrier integrity was determined by measurement of the apical-to-basolateral flux of a fluorescent marker [fluorescein sulfonic acid (FSA; 200 μ g/mL; 478Da)] by the formula of FSA clearance (nl/h/cm²) = Fab/([FSA]a)×S [30]. Fab is the apical-to-basolateral flux of FSA (light units/h), [FSA]a is the concentration at baseline (light units/nl) and S is the surface area (0.3cm²). Higher FSA represents more severe caco-2 monolayer mucosal dysfunction. Additionally, *mRNA*/protein expression levels in the caco-2 lysates were measured.

In vitro effects of calcitriol on NASH-V-CM/TNF α -induced lipogenesis on lean-V rat hepatocytes

After isolation and standard preparation [29,31], lean-V rat hepatocytes (5×10^5) were cultured with buffer, TNF α , or NASH-V-CM in the presence or absence of 1,25(OH)₂D₃ for 36 hours. Following this, oil red O stain-based measurement of intracellular TG accumulation was carried out. In parallel, expression of various *mRNA*/protein in corresponding cell lysates was measured.

Statistical analysis. Data were analyzed using Graphpad Prism 4 (GraphPad Software, San Diego, CA) and expressed as means \pm S.D. Statistical significance for each group was determined using one-way ANOVA with *post hoc* multiple comparisons being performed using the Newman-Keuls test. When the criteria for parametric testing were validated, Mann-Whitney U-tests were performed. *P* value less than 0.05 was considered significant.




Fig 1. Chronic calcitriol treatment ameliorates hepatic steatosis and improved inflammatory profiles of monocytes. H-E (a) and O-red oil staining (b) for hepatic steatosis. (c) hepatic triglyceride content and (d) cytokines levels in the cell lysates of various rat monocytes. (e) A representative flow cytometric histogram/dot plots of the cytokines/cytokine receptors of NASH-V-rat monocytes. (f) A bar graph of the flow cytometry-assessed cytokines/cytokine receptors of monocytes from various rats. †*P* < 0.05, †† *P* < 0.01 vs. lean-V group; **P* < 0.05, ***P* < 0.01 vs. NASH-V group.

<https://doi.org/10.1371/journal.pone.0194867.g001>

Results

Notably, 14 weeks of high-fat diet (HFD) feeding induced typical NASH histology as well as high ALT, AST, fasting glucose and triglyceride levels in NASH-V rats (Fig 1A, Table 1). Significantly, the HE stain-assessed NAS scores, O-red-oil stain-assessed hepatic steatosis, hepatic triglyceride levels, body weight, and liver weight in NASH-V rats were higher than those in the lean-V rats (Fig 1A–1C, Table 1).

Correction of the hypo-vitaminemia D inhibits systemic/portal endotoxemia and systemic inflammatory profiles

Compared to lean-V rats, NASH-V rats were found to have higher levels of plasma TNF α , LBP, and plasma/portal endotoxin, as well as lower levels of plasma/intestinal calcitriol (Table 2). Compared to the NASH-V group, restoration of plasma calcitriol levels in NASH-vit.D rats by 10 weeks of calcitriol treatment was accompanied by the suppression of plasma and portal endotoxin levels as well as the reduction of LBP and TNF α levels (Table 2). Higher TNF α , TNFR1, NF κ B, and TLR4 expression in NASH-V rat monocytes than in the lean-V

Table 1. Basal characteristics of all rats.

	Lean-V (n = 6)	Lean-vit. D (n = 6)	NASH-V (n = 9)	NASH-vit.D (n = 9)
Body weight (gram)	399±17	406±19	508±49 ^{††}	462±30*
Liver weight (gram)	15.7±1.3	17.9±1.8	37.1±1.2 [†]	29.3±2.5*
[fasting glucose] (mg/dL)	107.5±4.8	98.7±10.5	227.3 ±8.1 [†]	165.4±9.2*
[Triglyceride] (mg/dL)	59±4	50±10	199±18 ^{††}	95±8**
[aspartate aminotransferase] (AST, U/L)	49.6±5.1	48.5±4.3	111.4±3.5 [†]	80.7± 8.6*
[alanine aminotransferase] (ALT, U/L)	45.8±6.2	35.9±4.7	91.7±6.2 ^{††}	70.7±3.9**

Data were expressed as mean ±SD;

[†]P<0.05,

^{††} P<0.01 vs. lean-V rat's data;

* P <0.05,

**P<0.01 vs. NASH-V rat's data.

<https://doi.org/10.1371/journal.pone.0194867.t001>

group was observed and this was accompanied by lower vitamin D receptor (VDR) expression (Fig 1D–1F). Significantly, 10 weeks of calcitriol treatment suppressed the TNFα, TNFRI, NFκB and TLR4 expression and normalized VDR expression in the NASH rat monocytes (Fig 1D–1F). Nonetheless, no significant difference in the aforementioned markers was found when lean-V and lean-vit.D groups were compared.

Chronic calcitriol treatment suppresses intestinal hyper-permeability and intestinal pathogenic signals in NASH rats

In NASH-V rats, intestinal hyper-permeability (DX-4000-FITC and fecal albumin-based assays) and down-regulated tight-junction proteins (ZO-1 and occludin) expressions were associated with the decreased intestinal VDR and increased intestinal TNFα, TNFRI, caspase-7, Bax and MLCK levels (Fig 2A–2D). Furthermore, the aforementioned intestinal abnormalities were significantly suppressed in NASH-V rats (Figs 2 and 3A).

Table 2. Various pathogenic markers in all rats.

	Lean-V (n = 6)	Lean-vit. D (n = 6)	NASH-V (n = 9)	NASH-vit.D (n = 9)
[Calcitriol, 1,25(OH) ₂ D ₃ , pg/mL]	12.1±0.4	14.8±1.3	4.6±1.1 ^{††}	11.9±2.1**
[Endotoxin, EU/mL]	3.8±0.4	3.2±0.2	17.8±2.3 ^{††}	8.8±1.1**
Portal venous endotoxin levels [EU/mL]	4.1±0.08	3.7±0.05	19.5±1.1 ^{††}	9.4±0.9**
[TNFα, pg/mL]	4.8±1.1	4.1± 0.7	22.1±3.5 ^{††}	13.9±2.1*
[LPS binding protein, LBP, ng/mL]	309±13	252±28	4239±547 ^{††}	2520±438**
Bacterial-translocation (BT rate, %) positive culture of mesenteric lymph node (MLN)	0	0	6/9 (67%) ^{††}	3/9(33%) *
Intestinal calcitriol [1,25(OH) ₂ D ₃ , pg/gram]	80±11	82±7	41±8 ^{††}	69±10 *
Intestinal caspase-3 activity (fold changes compared to lean-V)	1	0.9±0.2	4.3±0.5 [†]	2.9±0.4*
Hepatic TNFα levels (pg/mg protein)	25±1	22±4	66±3 [†]	42±7*
Hepatic MCP-1 levels (pg/mg protein)	220±11	198±23	519±16 ^{††}	403±38*
Hepatic IL-6 levels (pg/mg protein)	27±3	21±8	58±17 [†]	42±19*

Data were expressed as mean ±SD;

[†]P<0.05,

^{††} P<0.01 vs. lean-V rat's data;

* P <0.05,

**P<0.01 vs. NASH-V rat's data.

<https://doi.org/10.1371/journal.pone.0194867.t002>




Fig 2. Chronic calcitriol treatment normalizes intestinal VDR expression and improves intestinal hyper-permeability in NASH rats. DX-4000 FITC-based (a) and fecal albumin-based (b) assessment of intestinal permeability. The expression of various proteins (c) and mRNAs (d) in intestines from different groups of rat; AUC: area under curves; $^{\dagger}P < 0.05$, $^{\dagger\dagger}P < 0.01$ vs. lean-V group; $*P < 0.05$, $**P < 0.01$ vs. NASH-V group.

<https://doi.org/10.1371/journal.pone.0194867.g002>

Significantly, intestinal hyper-permeability was associated with an abundance of *Bacteroides-Prevotella* and a reduction in *Lactobacillus* ($\downarrow 89\%$) and *Bifidobacterium* ($\downarrow 79\%$) numbers in NASH-V rats. However, the improvement in intestinal hyperpermeability in NASH-vit. D rats was not accompanied by the reversal of rat gut microbiota changes (Table 3).


Intestinal hyper-permeability parallels to the portal endotoxemia and tissue inflammation in NASH rats

Notably, the intestinal hyper-permeability was associated with portal endotoxemia and increased hepatic/MAT/intestinal macrophage infiltration, inflammation and corresponding cytokines levels (IL-6, MCP-1, *F4/80*, $\text{TNF}\alpha$, *NFkBp65*, TNFRI and TLR4) in NASH-V rats (Tables 1 and 2, Figs 2C, 2D, 3 and 4).

Chronic calcitriol treatment suppresses MAT inflammation and reduces the inflammatory profiles of NASH-V rat adipocytes

Compared to the lean-V group, a significant increase in the number of infiltrated macrophages in MAT was noted in the NASH-V group (Fig 4A). In addition, the releases of $\text{TNF}\alpha$,

A Images/bars IHC staining of doudenum



B Representative images and bar graph of number of macrophages in small intestine




Fig 3. Chronic calcitriol treatment improved intestinal inflammation in NASH rats. The expression of various proteins (a) in the intestines from various different groups of rat and the flow-cytometry-based analysis of macrophage infiltration in the same rat (b) small intestine. †*P*<0.05, ††*P*<0.01 vs. lean-V group; **P*< 0.05, ***P*<0.01 vs. NASH-V group.

<https://doi.org/10.1371/journal.pone.0194867.g003>

MCP-1 and IL-6 from MAT-derived adipocytes was higher in the NASH-vit. D group than that in the NASH-V group (Fig 4B). In lean-V rat adipocytes cultures, NASH-V-CM and TNFα induce the release of aforementioned cytokines and up-regulated the *TNFR1/NFκB* expressions in cell lysates, which were dose-dependently abolished by vitamin D co-incubation (Fig 4C and 4D).

Table 3. Quantification of total number of bacterial cells of the intestinal flora in cecal content.

	Lean-V	Lean-vit. D	NASH-V	NASH-vit.D
<i>Lactobacillus</i> spp. (cells/g cecal content)	7.1×10 ⁸ ±2.9×10 ⁸	8.5×10 ⁸ ±3.6×10 ⁸	2.3×10 ⁷ ±0.49×10 ⁷ †	2.9×10 ⁷ ±0.86×10 ⁷
<i>Bifidobacterium</i> spp. (cells/g cecal content)	5.3×10 ⁶ ±1.4×10 ⁶	6.8×10 ⁶ ±0.9×10 ⁶	1.4×10 ⁴ ±0.57×10 ⁴ ††	6.6×10 ⁴ ±0.89×10 ⁴
<i>Bacteroides-Prevotella</i> spp. (cells/g cecal content)	4.9×10 ⁸ ±0.43×10 ⁸	1.1×10 ⁸ ±0.23×10 ⁸	2.9×10 ⁹ ±0.55×10 ⁹ †	1.9×10 ⁸ ±0.27×10 ⁸

Data were expressed as mean ±SD;

†*P*<0.05,

†† *P*<0.01 vs. lean-V rat's cecal content.

<https://doi.org/10.1371/journal.pone.0194867.t003>




Fig 4. Chronic calcitriol treatment suppresses mesenteric adipose tissue (MAT) inflammation of NASH rats. (a) A flow-cytometry-based analysis of macrophage infiltration in rat MAT. (b) The cytokines levels in the supernatant of MAT-derived adipocytes collected from different groups of rats. (c) The expression levels of mRNA in the cell lysates of lean-V rat adipocytes after various treatments. (d) The peak levels of cytokine releases in the supernatant of NASH-V rat adipocytes after various treatments; † $P < 0.05$, †† $P < 0.01$ vs. lean-V/buffer group; * $P < 0.05$, ** $P < 0.01$ vs. NASH-V-CM/TNF α group.

<https://doi.org/10.1371/journal.pone.0194867.g004>

Acute calcitriol incubation prevents NASH-V-CM/TNF α -induced caco-2 monolayer mucosal dysfunction

Fig 5A and 5B revealed that NASH-V-CM and TNF α induced barrier dysfunction and caused a decrease in the IF-evaluated ZO-1 stained positive area of caco-2 monolayers. These changes were accompanied by down-regulation of VDR, ZO-1 and occludin expression, as well as up-regulation of caspase-3, caspase-7, Bax, and MLCK expression in caco-2 cell lysates (Fig 5C and 5D). Dose-dependently, incubation with vitamin D normalized the aforementioned NASH-V-CM and TNF α -induced changes in the caco-2 cells culture system (Fig 5).

Acute calcitriol incubation prevents NASH-V-CM/TNF α -induced lean-V rat hepatocytes' lipogenesis

Compared to the buffer group, NASH-V-CM and TNF α (25ng/mL) significantly increased the intracellular triglyceride content of lean-V rat hepatocytes (Fig 6A). Furthermore, the HFD-V-CM and TNF α -induced lean-V rat hepatocyte lipogenesis was accompanied by up-




Fig 5. *In vitro* effects of calcitriol on the NASH-V-CM and TNF α -induced mucosal dysfunction in caco-2 cells. (a,b) The *in vitro* effects of various treatments on caco-2 monolayer mucosal dysfunction and IF-stained ZO-1 expression. (c,d) protein and mRNA levels in the cell lysates of caco-2 monolayer cells after various treatments. [†]*P*<0.05, ^{††}*P*<0.01 vs. lean-V group; **P*< 0.05, ***P*<0.01 vs. NASH-V-CM group.

<https://doi.org/10.1371/journal.pone.0194867.g005>

regulation of *TNFR1/NFκBp65* as well as lipogenic signals in the cell lysates (Fig 6B and 6C). Notably, incubation with vitamin D dose-dependently reversed the aforementioned NASH-V-CM and TNF α -induced changes in the lean-V rat hepatocyte culture system (Fig 6A–6C).

Discussion

Increased TNF α -TNFR1 gene expression and elevated soluble TNF α levels are well-recognized pathogenic factors for NASH development [32,33]. Vitamin D can suppress TNF- α and IL-6 production by activated-monocytes in type 2 diabetic patients [34]. In cultured peritoneal macrophages of patients undergoing peritoneal dialysis, vitamin D dose-dependently inhibit LPS-stimulated TNF α release [35]. Our study reveals that the cytokines (TNF- α , IL-6, and MCP-1) released from NASH-V rat monocytes is higher than those in the lean-V group. Significantly, in our study, chronic vitamin D treatment inhibited the cytokines levels in monocytes of NASH-vit. D rats compared to those in NASH-V rats. TNF α -mediated inflammatory responses are mainly mediated by TNFR1 [36]. So, it is reasonable to observe that TNF α -




Fig 6. *In vitro* effects of calcitriol on the NASH-V-CM and TNF α -induced lipogenesis in lean-V rat hepatocytes. (a) representative micrographs of intracellular lipogenesis in lean-V rat hepatocytes after various different treatments. (b,c) The cytokines levels, lipogenic protein/*mRNA* levels in the cell lysates of lean-V rat hepatocytes after various treatments. $^{\dagger}P < 0.05$, $^{\dagger\dagger}P < 0.01$ vs. buffer-group; $^*P < 0.05$, $^{**}P < 0.01$ vs. NASH-V-CM-group/TNF α -group.

<https://doi.org/10.1371/journal.pone.0194867.g006>

related effects were found to be mediated by the TNFR1-NF κ B pathway in monocytes and the tissues of NASH-V rats.

Vitamin D and vitamin D receptors (VDRs) are important regulators of intestinal inflammation [18,19,31,37]. In particular, vitamin D and VDR deficiency exacerbates experimental inflammatory bowel disease (IBD) [18,19,37]. It is reported that VDR gene-knockout mice develop severe intestinal inflammation in experimental models of IBD [37–39]. *In vitro* studies have shown that vitamin D protects against dextran sodium sulfate (DSS)-induced disruption of intestinal epithelial tight junctions [40,41]. In our NASH rats, the intestine VDR expression was negatively correlated with the animals' intestinal TNF α levels, intestinal hyper-permeability and tight junction protein expression and these could be corrected by chronic vitamin D treatment.

Binding of TNF α to TNFR, which activates myosin light chain kinase (MLCK) and NF κ B in intestinal epithelial cells can result in epithelial mucosal barrier dysfunction [40–42]. Intestinal MLCK over-expression has been reported in patients with ulcerative colitis and Crohn's disease [43]. Up-regulated MLCK and NF κ B can induce apoptosis and rearrangement of tight

junction proteins, including occludin and ZO-1 [40,41–43]. In our NASH rats receiving chronic vitamin D treatment, down-regulation of intestinal TNF α -TNFR1-NF κ B signals prevented intestinal apoptotic activity and preserved the integrity of the intestinal mucosal barrier by decreasing MLCK expression and normalizing tight-junction protein expression. In our caco-2 cell system, TNF α and the supernatant of cultured NASH-V rat monocytes could induce monolayer mucosal dysfunction and the corresponding pathogenic signals, which could be inhibited by vitamin D co-incubation.

In experimental colitis models, 1,25(OH)₂vitamin D₃ has been found to suppress intestinal mucosal injury, decrease intestinal inflammation and maintain the integrity of the intestinal mucosal barrier [38,39]. A negative correlation has been noted between serum vitamin D and bacterial-translocation in HIV/hepatitis C virus co-infected patients [44]. High LBP levels and MLN positive culture rates are representative markers for increased bacterial-translocation [44,45]. In our NASH rats receiving vitamin D treatment, normalization of plasma/tissue calcitriol and VDR levels was accompanied by a decrease in the MLN positive culture rate and in plasma LBP levels. In addition to bacterial-translocation, alteration in gut microbiota is known to be involved in the progression of NASH [3,13,14]. Modulation of gut microbiota ameliorates obesity-associated impaired intestinal mucosal integrity and bacterial-translocation in rats [13,14]. In our study, the lack of an effect of chronic vitamin D treatment on the gut microbiota indicates that the benefits of chronic vitamin D treatment in our NASH-vit.D rats involved other mechanisms.

In our lean rat mesenteric adipose tissue (MAT)-derived adipocytes, TNF α and the supernatant of cultured NASH-V rat monocytes induced cytokines release, which could be inhibited by vitamin D co-incubation. The blood and lymphatic vessels draining the gut are embedded in MAT [46]. In NASH animals with endotoxemia, there is a positive regulatory loop between intestinal mucosal barrier dysfunction and MAT inflammation [6,8]. In our NASH rats, vitamin D treatment-related correction of intestinal mucosal barrier dysfunction was accompanied by an improvement in MAT inflammation and a reduction in endotoxemia. In fact, a causal link has been reported between the HFD-induced gut inflammation and the activated inflammatory profile in MAT adjacent to the inflamed intestine [10]. In inflamed adipose tissue, vitamin D can suppress the TNF α and NF κ B-mediated cytokines release [47,48]. In NAFLD patients, vitamin D deficiency has been reported to increase the risk of NASH via activation of NF κ B signals [17,49]. So, it is reasonable to observe in our NASH rats that macrophage infiltration, inflammation, and TNF α -NF κ B-mediated cytokines release in gut and adipose tissues were simultaneously inhibited by chronic vitamin D treatment.

Blood from the portal vein drains to the liver and thus, the liver is exposed to relatively high concentrations of TNF α and IL-6 released by the inflamed gut and MAT [50]. Both *in vivo* and *in vitro* studies have reported that TNF α and IL-6 can exacerbate hepatic steatosis [51–53]. TNF α can activate NF κ B and stimulate IL-6 production from hepatocytes [54]. Vitamin D treatment suppresses hepatic lipogenesis by down-regulation of lipogenic signals [23,25,55]. In our study, chronic vitamin D treatment decrease hepatic steatosis by suppressing the levels of TNF α , NF κ B and IL-6 in NASH rat livers. Additionally, in an *in vitro* study, the suppression of TNF α -TNFR1-NF κ B signaling and corresponding lipogenesis by vitamin D co-incubation was observed in lean rat hepatocytes.

In conclusion, our study suggests that systemic/portal endotoxemia, intestinal inflammation, intestinal hyper-permeability, together with up-regulation of TNF α -mediated signaling contribute to down-regulation of VDR expression in monocytes as well as within the intestine of NASH rats. Furthermore, intestinal hyper-permeability exacerbates bacterial translocation to mesenteric lymph nodes and mesenteric adipose tissue inflammation; this subsequently leads to TNF α -TNFR1-NF κ B-mediated hepatic steatosis in NASH rats. Intriguingly, the

intestinal VDR deficiencies as well as the related TNF α -TNFR1-NF κ B-mediated gut/adipose/liver abnormalities can be effectively attenuated by chronic calcitriol treatment in NASH animals. So, in addition to diet control and exercise, chronic use of vitamin D may be a promising strategy for the improvement of NASH.

Supporting information

S1 Table. Primer of rat gene used for quantitative realtime PCR analysis.
(DOCX)

S1 Fig. Chronic calcitriol treatment dose-dependently inhibits hepatic steatosis and serum/intestinal TNF α levels of NASH-V rats.
(TIF)

S1 File. Supplement materials and methods.
(DOCX)

S2 File. Laboratory protocols of the procedure of isolation of adipocytes from rat mesenteric adipose tissue (MAT) in protocols.io.
(DOCX)

S3 File. Data of this study.
(XLSX)

Acknowledgments

We especially thank Yun-Ru Wang, Fan-Yi Jhan, Che-Jui Chang and Yen-Ling Lin for their excellent technical supports.

Author Contributions

Conceptualization: Hung-Cheng Tsai, Shiang-Fen Huang, Ying-Ying Yang.

Data curation: Chia-Chang Huang.

Formal analysis: Chia-Chang Huang.

Funding acquisition: Ying-Ying Yang, Han-Chieh Lin.

Investigation: Yen-Bo Su, Yun-Cheng Hsieh.

Methodology: Hung-Cheng Tsai, Yun-Cheng Hsieh.

Project administration: Tzu-Hao Li, Ying-Ying Yang, Ming-Chih Hou, Han-Chieh Lin.

Resources: Ying-Ying Yang, Yi-Hsiang Huang.

Software: Tzu-Hao Li.

Supervision: Ying-Ying Yang, Yi-Hsiang Huang, Ming-Chih Hou, Han-Chieh Lin.

Validation: Tzu-Hao Li, Shiang-Fen Huang, Ying-Ying Yang.

Writing – original draft: Yen-Bo Su.

References

1. Van der Bruggen T, Nijenhuis S, van Raaij E, Verhoef J, van Asbeck BS. Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the Raf-1/MEK1-MEK2/ERK1-ERK2 pathway. *Infect Immun*. 1999; 67(8): 3824–3829. PMID: [10417144](https://pubmed.ncbi.nlm.nih.gov/10417144/)

2. Poniachik J, Csendes A, Díaz JC, Rojas J, Burdiles P, Maluenda F, et al. Increased production of IL-1 α and TNF- α in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. *Cytokine*. 2006; 33(5): 252–257. <https://doi.org/10.1016/j.cyto.2006.02.006> PMID: 16564703
3. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. *Sci Rep*. 2015; 5:8096–8102. <https://doi.org/10.1038/srep08096> PMID: 25644696
4. Leppkes M, Roulis M, Neurath MF, Kollias G, Becker C. Pleiotropic functions of TNF- α in the regulation of the intestinal epithelial response to inflammation. *Int Immunol*. 2014; 26(9):509–515. <https://doi.org/10.1093/intimm/dxu051> PMID: 24821262
5. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. *Gut*. 2001; 48(2):206–211. <https://doi.org/10.1136/gut.48.2.206> PMID: 11156641
6. Liu H, Li M, Wang P, Wang F. Blockade of hypoxia-inducible factor-1 α by YC-1 attenuates interferon- γ and tumor necrosis factor- α -induced intestinal epithelial barrier dysfunction. *Cytokine*. 2011; 56(3):581–588. <https://doi.org/10.1016/j.cyto.2011.08.023> PMID: 21890376
7. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology*. 2009; 49(6):1877–1887. <https://doi.org/10.1002/hep.22848> PMID: 19291785
8. Lam YY, Ha CW, Campbell CR, Mitchell AJ, Dinudom A, Oscarsson J, et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. *PLoS One*. 2012; 7(3):e34233–e34232. <https://doi.org/10.1371/journal.pone.0034233> PMID: 22457829
9. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. *Am J Physiol Gastrointest Liver Physiol*. 2007; 292(2):G518–G525. <https://doi.org/10.1152/ajpgi.00024.2006> PMID: 17023554
10. Li H, Lelliott C, Håkansson P, Ploj K, Tuneld A, Verolin-Johansson M, et al. Intestinal, adipose, and liver inflammation in diet-induced obese mice. *Metabolism*. 2008; 57(12):1704–1710. <https://doi.org/10.1016/j.metabol.2008.07.029> PMID: 19013294
11. Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? *Expert Rev Gastroenterol Hepatol*. 2015; 9(8):1069–1076. <https://doi.org/10.1586/17474124.2015.1057122> PMID: 26088524
12. Gäbele E, Dostert K, Hofmann C, Wiest R, Schölmerich J, Hellerbrand C, et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. *J Hepatol*. 2011; 55(6):1391–1399. <https://doi.org/10.1016/j.jhep.2011.02.035> PMID: 21703208
13. Jiang T, Gao X, Wu C, Tian F, Lei Q, Bi J, et al. Apple-derived pectin modulates gut microbiota, improves gut barrier function, and attenuates metabolic endotoxemia in rats with diet-induced obesity. *Nutrients*. 2016; 8(3):126–145. <https://doi.org/10.3390/nu8030126> PMID: 26938554
14. Wang JH, Bose S, Kim GC, Hong SU, Kim JH, Kim JE, et al. Flos Ionicera ameliorates obesity and associated endotoxemia in rats through modulation of gut permeability and intestinal microbiota. *PLoS One*. 2014; 9(1):e86117–e86130. <https://doi.org/10.1371/journal.pone.0086117> PMID: 24475077
15. Müller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. *Cytokine*. 1992; 4(6):506–512. [https://doi.org/10.1016/1043-4666\(92\)90012-G](https://doi.org/10.1016/1043-4666(92)90012-G) PMID: 1337987
16. Peterson CA, Heffernan ME. Serum tumor necrosis factor- α concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. *J Inflamm*. 2008; 5:10–18. <https://doi.org/10.1186/1476-9255-5-10> PMID: 18652680
17. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. *Nutr Metab Cardiovasc Dis*. 2007; 17(7):517–524. <https://doi.org/10.1016/j.numecd.2006.04.002> PMID: 16928437
18. Chen Y, Du J, Zhang Z, Liu T, Shi Y, Ge X, et al. MicroRNA-346 mediates tumor necrosis factor α -induced down-regulation of gut epithelial vitamin D receptor in inflammatory bowel diseases. *Inflamm Bowel Dis*. 2014; 20(11):1910–1918. <https://doi.org/10.1097/MIB.000000000000158> PMID: 25192497
19. Li YC, Chen Y, Du J. Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation. *J Steroid Biochem Mol Biol*. 2015; 148:179–183. <https://doi.org/10.1016/j.jsbmb.2015.01.011> PMID: 25603468

20. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. *J Hepatol*. 2011; 55(2):415–425. <https://doi.org/10.1016/j.jhep.2010.11.028> PMID: 21184788
21. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. *Hepatology*. 2012; 55(4):1103–11. <https://doi.org/10.1002/hep.24737> PMID: 21994008
22. Han H, Cui M, You X, Chen M, Piao X, Jin G. A role of 1,25(OH)₂D₃ supplementation in rats with nonalcoholic steatohepatitis induced by choline-deficient diet. *Nutr Metab Cardiovasc Dis*. 2015; 25(6):556–61. <https://doi.org/10.1016/j.numecd.2015.02.011> PMID: 25843661
23. Liu XJ, Wang BW, Zhang C, Xia MZ, Chen YH, Hu CQ, et al. Vitamin D Deficiency Attenuates High-Fat Diet-Induced Hyperinsulinemia and Hepatic Lipid Accumulation in Male Mice. *Endocrinology*. 2015; 156(6):2103–2113. <https://doi.org/10.1210/en.2014-2037> PMID: 25774554
24. Chang E, Kim Y. Vitamin D insufficiency exacerbates adipose tissue macrophage infiltration and decreases AMPK/SIRT1 activity in obese rats. *Nutrients*. 2017; 9(4):338–352. <https://doi.org/10.3390/nu9040338> PMID: 28353634
25. Liu L, Lv G, Ning C, Yang Y, Zhu J. Preventive and therapeutic effect of 1,25-dihydroxyvitamin D₃ on non-alcoholic steatohepatitis of rats. *Exp Ther Med*. 2016; 11(6):2284–2292.
26. Manna P, Achari AE, Jain SK. Vitamin D supplementation inhibits oxidative stress and upregulate SIRT1/AMPK/GLUT4 cascade in high glucose-treated 3T3L1 adipocytes and in adipose tissue of high fat diet-fed diabetic mice. *Arch Biochem Biophys*. 2017; 615:22–34. <https://doi.org/10.1016/j.abb.2017.01.002> PMID: 28063949
27. Drori A, Rotnemer-Golinkin D, Avni S, Drori A, Danay O, Levanon D, et al. Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift. *BMC Gastroenterol*. 2017; 17(1):130–139. <https://doi.org/10.1186/s12876-017-0688-4> PMID: 29179679
28. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLoS Biol*. 2010; 8:e1000412–e1000416. <https://doi.org/10.1371/journal.pbio.1000412> PMID: 20613859
29. Duarte MS, Wei S, Paulino PVR, Du M, Jiang Z, Zan L, et al. Isolation of mature adipocytes and stromal vascular cells under adverse sampling conditions. *J Metabolic Syndr*. 2012; 1:4–7. <https://doi.org/10.4172/2167-0943.1000112>
30. Unno N, Menconi MJ, Salzman AL, Smith M, Hagen S, Ge Y, et al. Hyperpermeability and ATP depletion induced by chronic hypoxia or glycolytic inhibition in Caco-2B Be monolayers. *Am J Physiol*. 1996; 270:G1010–1021. <https://doi.org/10.1152/ajpgi.1996.270.6.G1010> PMID: 8764209
31. Cantorna MT. Mechanisms underlying the effects of vitamin D on the immune system. *Proc Nutr Soc*. 2010; 69:286–289. <https://doi.org/10.1017/S0029665110001722> PMID: 20515520
32. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Domínguez-Díez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. *Hepatology*. 2001; 34:1158–1163. <https://doi.org/10.1053/jhep.2001.29628> PMID: 11732005
33. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. *Gut*. 2006; 55(3):415–424. <https://doi.org/10.1136/gut.2005.071118> PMID: 16174657
34. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. *Diabetes Res Clin Pract*. 2007; 77(1):47–57. <https://doi.org/10.1016/j.diabres.2006.10.007> PMID: 17112620
35. Cohen ML, Douvdevani A, Chaimovitz C, Shany S. Regulation of TNF-alpha by 1alpha, 25-dihydroxyvitamin D₃ in human macrophages from CAPD patients. *Kidney Int*. 2001; 59(1): 69–75. <https://doi.org/10.1046/j.1523-1755.2001.00467.x> PMID: 11135059
36. Devin A, Lin Y, Yamaoka S, Li Z, Karin M, Liu Zg. The alpha and beta subunits of IκappaB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. *Mol Cell Biol*. 2001; 21(12):3986–3994. <https://doi.org/10.1128/MCB.21.12.3986-3994.2001> PMID: 11359906
37. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel disease. *Mol Endocrinol* 2003; 17:2386–2392. <https://doi.org/10.1210/me.2003-0281> PMID: 14500760

38. Kong J, Zhang Z, Musch MW, Ning G, Sun J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. *Am J Physiol Gastrointest Liver Physiol*. 2008; 294:G208–216. <https://doi.org/10.1152/ajpgi.00398.2007> PMID: 17962355
39. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, et al. Protective role of 1,25(OH)₂ vitamin D₃ in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. *BMC Gastroenterol*. 2012; 12:57–70. <https://doi.org/10.1186/1471-230X-12-57> PMID: 22647055
40. Su L, Nalle SC, Shen L, Turner ES, Singh G, Breskin LA, et al. TNFR2 activates MLCK-dependent tight junction dys-regulation to cause apoptosis-mediated barrier loss and experimental colitis. *Gastroenterology*. 2013; 145(2):407–415. <https://doi.org/10.1053/j.gastro.2013.04.011> PMID: 23619146
41. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, et al. TNF- α -induced increase in intestinal epithelial tight junction permeability requires NF- κ B activation. *Am J Physiol Gastrointest Liver Physiol*. 2004; 286(3):G367–376. <https://doi.org/10.1152/ajpgi.00173.2003> PMID: 14766535
42. Feng Y, Teitelbaum DH. Tumour necrosis factor- α -induced loss of intestinal barrier function requires TNFR1 and TNFR2 signalling in a mouse model of total parenteral nutrition. *J Physiol*. 2013; 591(Pt 15):3709–3723. <https://doi.org/10.1113/jphysiol.2013.253518> PMID: 23753529
43. Blair SA, Kane SV, Clayburgh DR, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. *Lab Invest*. 2006; 86(2):191–201. <https://doi.org/10.1038/labinvest.3700373> PMID: 16402035
44. García-Álvarez M, Berenguer J, Jiménez-Sousa MÁ, Vázquez-Morón S, Carrero A, Gutiérrez-Rivas M, et al. Optimal vitamin D plasma levels are associated with lower bacterial DNA translocation in HIV/hepatitis C virus coinfecting patients. *AIDS*. 2016; 30(7):1069–1074. <https://doi.org/10.1097/QAD.0000000000001007> PMID: 27032111
45. Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. *PLoS One*. 2013; 8(1):e54600–e54607. <https://doi.org/10.1371/journal.pone.0054600> PMID: 23349936
46. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. *Proc Nutr Soc*. 2001; 60(3):329–339. <https://doi.org/10.1079/PNS200194> PMID: 11681807
47. Ding C, Wilding JP, Bing C. 1,25-dihydroxyvitamin D₃ protects against macrophage-induced activation of NF κ B and MAPK signalling and chemokine release in human adipocytes. *PLoS One*. 2013; 8(4):e61707–61720. <https://doi.org/10.1371/journal.pone.0061707> PMID: 23637889
48. Gao D, Trayhurn P, Bing C. 1,25-Dihydroxyvitamin D₃ inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. *Int J Obes*. 2013; 37(3):357–365. <https://doi.org/10.1038/ijo.2012.53> PMID: 22508334
49. Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-Stevenson V, et al. Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: possible role for MAPK and NF- κ B? *Am J Gastroenterol*. 2016; 111(6):852–863. <https://doi.org/10.1038/ajg.2016.51> PMID: 27002799
50. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of Type 2 diabetes: molecular mechanisms and probiotic treatment. *EMBO Mol Med*. 2011; 3:559–572. <https://doi.org/10.1002/emmm.201100159> PMID: 21735552
51. Feingold KR, Grunfeld C. Tumor necrosis factor- α stimulates hepatic lipogenesis in the rat *in vivo*. *J Clin Invest*. 1987; 80(1):184–190. <https://doi.org/10.1172/JCI113046> PMID: 3597772
52. Grunfeld C, Dinarello CA, Feingold KR. Tumor necrosis factor- α , interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells. *Metabolism*. 1991; 40(9):894–898. [https://doi.org/10.1016/0026-0495\(91\)90062-2](https://doi.org/10.1016/0026-0495(91)90062-2) PMID: 1654497
53. Vida M, Gavito AL, Pavón FJ, Bautista D, Serrano A, et al. Chronic administration of recombinant IL-6 up-regulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice. *Dis Model Mech*. 2015; 8(7):721–731. <https://doi.org/10.1242/dmm.019166> PMID: 26035386
54. Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K. Involvement of a NF- κ B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. *Mol Cell Biol*. 1990; 10:561–568. <https://doi.org/10.1128/MCB.10.2.561> PMID: 2405250
55. Kang EJ, Lee JE, An SM, Lee JH, Kwon HS, Kim BC, et al. The effects of vitamin D₃ on lipogenesis in the liver and adipose tissue of pregnant rats. *Int J Mol Med*. 2015; 36(4):1151–1158. <https://doi.org/10.3892/ijmm.2015.2300> PMID: 26239543